Research programme: thyroid hormone receptor beta agonists - Karo Pharma

Drug Profile

Research programme: thyroid hormone receptor beta agonists - Karo Pharma

Alternative Names: KB-141

Latest Information Update: 21 Dec 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Karo Bio
  • Class Phenyl ethers; Phenylacetates
  • Mechanism of Action Thyroid hormone receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 06 May 2004 Bristol-Myers Squibb announced its decision to return rights to the lead compound to Karo Bio and discontinued internal development on this programme
  • 06 May 2004 Preclinical trials in Obesity in Sweden (unspecified route)
  • 23 Sep 2003 A preclinical study has been added to the Obesity pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top